Venmax Drugs and Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
For the six months, revenue was INR 1 million. Net income was INR 0.148 million compared to net loss of INR 0.685 million a year ago. Basic earnings per share from continuing operations was INR 0.03 compared to basic loss per share from continuing operations of INR 0.13 a year ago. Diluted earnings per share from continuing operations was INR 0.03 compared to diluted loss per share from continuing operations of INR 0.13 a year ago.